HE4 Serum Levels are Associated with Poor Prognosis in Patients with Acute Heart Failure Combined with Chronic Kidney...

Area of Science:

• Cardiology
• Nephrology
• Biomarkers

Background:

• Human epididymis protein 4 (HE4) is implicated in acute heart failure (AHF) and chronic kidney disease (CKD) prognoses.
• The prognostic value of HE4 in patients with comorbid AHF and CKD requires further elucidation.

Purpose of the Study:

• To investigate the predictive capability of serum HE4 levels for clinical outcomes in patients diagnosed with both AHF and CKD.
• To determine if HE4 serves as an independent prognostic marker in this specific patient cohort.

Main Methods:

• Prospective enrollment of 130 patients with AHF and CKD from March 2019 to December 2022.
• Serum HE4 levels measured via chemiluminescence microparticle immunoassay.
• Endpoint events defined as heart failure readmission and cardiovascular death, analyzed using multivariable Cox regression and Kaplan-Meier curves.

Main Results:

• Elevated HE4 levels (>276.15 pmol/L) were significantly associated with a higher incidence of endpoint events (Log rank test: χ2=19.689, P < 0.001).
• Multivariable Cox analysis identified LnHE4 (HR=2.280, P = 0.004) and age as independent predictors of adverse outcomes.
• Adjusted analysis confirmed HE4 as a significant predictor (HR=2.520, P < 0.001).

Conclusions:

• Serum HE4 is an independent predictor of heart failure readmission and cardiovascular death in patients with AHF and CKD.
• HE4 measurement can aid in risk stratification for patients with combined AHF and CKD.